'/%3E%3C/svg%3E%0A){kind=small}
Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.
Prothena’s wholly owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aβ (amyloid beta) and PRX123, the company’s dual Aβ-tau vaccine. Prothena’s collaborations include prasinezumab, which targets alpha-synuclein, with Roche for the potential treatment of Parkinson’s disease; coramitug (PRX004) for the potential treatment of ATTR amyloidosis with Novo Nordisk; and programs that target tau (BMS-986446/PRX005) and an undisclosed target (PRX019) with Bristol Myers Squibb for the potential treatment of neurodegenerative diseases.
Program/Indication
Protein Target
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Global Partner4
PrasinezumabParkinson’s disease
α-Synuclein
(C-terminus)
Transthyretin
(misTTR)
PRX019Neurodegeneration
Undisclosed Target
UndisclosedAD in Down syndrome
Undisclosed Target
Aβ, Abeta; AD, Alzheimer’s disease; mAb, monoclonal antibody.
¹ Primary endpoint of all-cause mortality at p≤0.10 under the Special Protocol Assessment (SPA) agreement with FDA; ² Orphan Drug Designation granted by FDA & EMA; ³ FDA Fast Track designation; ⁴ In July 2021 Novo Nordisk acquired coramitug (formerly PRX004) and broader ATTR amyloidosis program and gained full worldwide rights. Prothena is eligible to receive up to $1.23 billion in total consideration.
mAb
Small Molecule
Vaccine
